Botulinum toxin complications: an overview

Botulinum toxin has a well-known safety profile when properly indicated, but it is not free of complications. Most are local, mild and temporary, because the effect of the toxin is reversible. What matters in practice is recognizing the picture, linking the sign to the likely muscle, separating what is expected from what is a warning and calmly managing a patient who is often frightened by their own face.

This guide is an overview at a review level. It does not include doses, injection points or medication protocols, which are decisions for the licensed professional, according to the product's package insert and the rules of their professional council. The mechanism of action is in botulinum toxin in orofacial harmonization: fundamentals, and the version written for the lay patient is in botox side effects.

How to think about toxin complications?

Almost every toxin complication fits into one of these four groups:

Thinking this way helps with management. A local reaction resolves in days. An effect on a neighboring muscle lasts as long as the toxin effect. A systemic sign changes the level of urgency.

What can happen in each area?

Eyes and eyelids

The periorbital region concentrates the complications that frighten patients most. Eyelid ptosis appears when toxin injected in the glabella or near the orbital rim reaches the muscle that lifts the upper eyelid. It has its own page: ptosis after botulinum toxin, with types, timeline and management.

Besides ptosis, the following appear:

• Dry eye or incomplete closure, when the orbicularis oculi becomes too weak. The patient reports burning, tearing or a gritty feeling.
• Lower eyelid sitting lower or a "wide-eyed" look, in skin with little support, when the lower portion of the orbicularis loses strength.
• Double vision (diplopia), rare, when the toxin reaches a muscle that moves the eye. It calls for quick assessment and, generally, an ophthalmology referral.
• More evident bags and malar swelling, in people who already had a tendency, from the loss of orbicularis pumping.

Brow and forehead

The frontalis muscle is the only brow elevator. Weakening it too much drops the brow and weighs on the eyelid; weakening only the central part can leave the tail of the brow peaking. Treating the glabellar depressors, such as the corrugator, without looking at the frontalis, or the reverse, draws brows the patient does not recognize. The complaint of a "frozen forehead" or an expressionless look also belongs here.

Mouth, smile and chin

The lower third is less forgiving of error, because the muscles are small, close together and all take part in speech and eating:

• Weakened orbicularis oris: difficulty whistling, using a straw, pronouncing some letters or holding liquids. The complaint usually comes from the patient who had lip botox.
• Depressor anguli oris and neighbors: if the toxin reaches the muscle that lowers the lower lip, the smile becomes asymmetric and shows fewer lower teeth on one side.
• Mentalis: excess effect can affect the position and seal of the lower lip.
• Gummy smile: upper lip too long or an asymmetric smile.
• Crow's feet with an effect on the zygomaticus major: the mouth corner rises less on one side when smiling.

Neck

When injecting the platysma, the main concern is the toxin reaching deeper neck muscles involved in swallowing, speech and head support. Difficulty swallowing, an altered voice or weakness lifting the head while lying down call for immediate assessment and should not be treated as a cosmetic effect.

Masseter

In the masseter, the most described complaints are fatigue when chewing, an altered smile when the toxin reaches the anterior smile muscles, paradoxical bulging when clenching the teeth and a hollowed look in those with laxity. The details are in botulinum toxin in the masseter.

When does the complication appear?

The timeframes vary with the product, the dose, the area and the patient.

Which systemic signs cannot be missed?

Hypersensitivity reactions are also rare but described, ranging from hives to severe presentations. The medical history should record prior allergy to product components, neuromuscular disease, pregnancy and breastfeeding, use of medications that interact with neuromuscular transmission and recent injections elsewhere.

And when the toxin "doesn't take"?

Not every complaint is about too much effect. The patient who returns saying the toxin did nothing also presents a complication, and the cause can lie in several places:

• Expectation: static wrinkles do not disappear with toxin alone, and the effect takes days to set in.
• Product: storage, reconstitution and expiry outside what the package insert provides.
• Planning: insufficient dose or distribution for that patient's muscle strength.
• Individual response: there are reports of reduced response associated with neutralizing antibodies, discussed with frequent sessions and high doses.

Because units are not interchangeable between products, switching brands requires recalculating everything from the package insert. The differences are in differences between type A botulinum toxins.

What is the initial management, at a review level?

Management is the decision of the licensed professional, according to the rules of their professional council, with a medical referral when indicated. In general terms:

1. Assess in person. A photo sent by message helps with triage, but does not settle the diagnosis.
2. Rule out systemic warning signs before anything else.
3. Link the sign to the likely muscle, comparing with the before photos, at rest and in movement.
4. Separate neighboring-muscle effect, excessive effect and local reaction, because each has a different timeline and management.
5. Assess functional impact: vision, eye closure, speech, eating, swallowing. Functional impact brings the referral forward.
6. Consider supportive measures, such as eye lubrication when the eye closes poorly or muscle balance adjustments in selected cases, always after diagnosis.
7. Do not re-inject blindly. More toxin without understanding the mechanism can worsen the picture.
8. Record in the patient record onset, photos, instructions, measures and follow-ups. Adverse events with regulated products can be reported to ANVISA (Brazil's health regulatory agency) through its reporting system.

How to explain it to the patient?

A patient with a toxin complication usually wants two answers: is it serious and will it pass. The conversation needs to be honest and without an exact timeframe.

The informed consent should mention the complications of the treated area. A starting point is the botulinum toxin consent template, reviewed with a lawyer and with the rules of your professional council.

And in Harmy?

Toxin complication checklist

1. Systemic signs ruled out or patient referred urgently.
2. In-person assessment done and photos compared with the before photos.
3. Likely muscle and complication group identified.
4. Functional impact assessed: eye, speech, eating, swallowing.
5. Supportive measures decided after diagnosis, without blind re-injection.
6. Patient given written instructions, with a contact channel and follow-ups scheduled.
7. Everything recorded in the patient record and, when applicable, reported.
8. Planning of upcoming sessions reviewed in light of what happened.